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Background: The development of whole smoke exposure systems have been driven by the fact that traditional
smoke exposure techniques are based on the particulate phase of tobacco smoke and not the complete smoke
aerosol. To overcome these challenges in this study, we used a Vitrocell® VC 10 whole smoke exposure system. For
characterisation purposes, we determined smoke deposition in relationship to airflow (L/min), regional smoke
deposition within the linear exposure module, vapour phase dilution using a known smoke marker (carbon
monoxide) and finally assessed biological responses using two independent biological systems, the Ames and
Neutral Red uptake (NRU) assay.
Results: Smoke dilution correlates with particulate deposition (R2 = 0.97) and CO concentration (R2 = 0.98). Regional
deposition analysis within the linear exposure chamber showed no statistical difference in deposited mass across
the chamber at any airflows tested. Biological analysis showed consistent responses and positive correlations with
deposited mass for both the Ames (R2 = 0.76) and NRU (R2 = 0.84) assays.
Conclusions: We conclude that in our study, under the experimental conditions tested, the VC 10 can produce
stable tobacco smoke dilutions, as demonstrated by particulate deposition, measured vapour phase smoke marker
delivery and biological responses from two independent in vitro test systems.
Keywords: Dosimetry, Particle deposition, QCM, Quartz crystal microbalance, CO, In vitro, Whole smoke, Vitrocell®Background
The association between tobacco smoke and disease is
widely understood [1-3] however, many of the disease
mechanisms that follow tobacco smoke exposure are
not. This is particularly driven by the fact that cigarette
smoke is a complex aerosol consisting of approximately
5600 chemicals [4], distributed between the vapour and
particulate phases. The vapour phase is the majority
fraction, between 90-95%, whereas the particulate phase
makes up only 5-10% by weight [5]. The particulate frac-
tion is mostly made up of phenols, esters, alkaloid deriv-
atives, terpenoids, alkanes, aldehydes and ketones, acids,
alcohols, nicotine and water. The vapour phase consists* Correspondence: David_Thorne@bat.com
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reproduction in any medium, provided the orof hydrocarbons, aldehydes and ketones, nitriles, heterocy-
clics, alcohols, acids, esters, hydrogen, helium, nitrogen,
carbon monoxide and dioxide and oxygen. Distributed
and partitioning unevenly between these two fractions are
biologically active chemicals, which have known toxico-
logical properties [6-8].
Over the last decade a great deal of focus has been
placed on the development of tobacco smoke or ‘whole
smoke’ related exposure systems [9-12]. This is partly
because traditional exposure techniques tend to focus
on the particulate phase of cigarette smoke [13,14] and
not the complete aerosol. Traditional techniques include
capturing the particulate fraction on a Cambridge filter
pad and eluting in dimethyl sulphoxide (DMSO) or bub-
bling the smoke aerosol through cell culture media or
phosphate buffered saline (PBS) to obtain a soluble frac-
tion. For both techniques, once the fraction is obtainedral Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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be exposed using submerged exposure conditions. Gener-
ating a particulate fraction using these techniques is rela-
tively easy and does not require specialised equipment,
ensuring a simple yet reliable compound for testing. Un-
fortunately, as a result, the full interactions of both phases
are not captured or assessed in vitro. Furthermore, separ-
ating smoke fractions may lead to alterations or chemical
changes which may not be representative of the complete
smoke aerosol [15]. There are a diverse range of whole
smoke exposure systems available ranging from commer-
cial set-ups to bespoke in-house designed and developed
exposure systems [16-18]. Commercially available systems
include those developed by Borgwaldt [19,20], Burghart
[21], CULTEX® [22,23] and Vitrocell® [24]. As yet, no ex-
posure system commercially available or otherwise has
been completely characterised or validated and each sys-
tem has advantages and disadvantages over the next [25].
Irrespective of origin, these systems generally have in com-
mon two main components: 1, a smoking machine, which
generates, dilutes and delivers cigarette smoke; 2, an ex-
posure chamber which houses the associated biological
system often at the air-liquid interface (ALI). Exposure of
in vitro biological systems to tobacco smoke poses many
logistical challenges. Not only does the smoke aerosol have
to be generated in a consistent manner but, it has to be
delivered evenly to the cell culture system and at aFigure 1 A schematic representation of the major components of the
controller and air-flow controller, which determines the smoking paramete
cigarettes are loaded and smoked, enclosed within an extraction ventilatio
Canada Intense puff (35 ml or 55 ml) of mainstream cigarette smoke to the
dilution system over 8 seconds, however this can be adjusted. [d] Dilution,
which multiple bars can make up the complete dilution system. Continuou
range 0.2-12 L/min and administered to the dilution bar through smoke ai
which can be upgraded to mass-flow controllers. Flow within the dilution
exposure module (Vitrocell® 6/4 CF Stainless Steel module or Vitrocell®-AME
the ALI or AAI. Smoke is sampled from the dilution system into the exposu
5 ml/min/well. Smoke is distributed within the exposure module via the sm
insert is isolated receiving an independent sample of smoke from the dilut
microbalances can be installed into each position or, as shown here, in pobiologically relevant dose. One such whole smoke expos-
ure system is the Vitrocell® VC 10 Smoking Robot
(Vitrocell® Systems GmbH, Waldkirch, Germany). The VC
10 is a rotary style smoking machine which has a single
syringe that transfers the mainstream cigarette smoke to
an independent continuous flow dilution system [24].
Smoke dilution in this system is achieved via turbulent
mixing, by adding air perpendicular to the stream of
smoke. Smoke dilutions are created by increasing or de-
creasing the diluting airflow. A vacuum sub-samples
smoke from the dilution system into the exposure module,
which docks directly under the continuous flow dilution
system. Inserts containing cells or a quartz crystal micro-
balance are then exposed at the ALI or air-agar-interface
(AAI) to diluted smoke from separate sample ports under
the dilution system (Figure 1).
At present, smoke generation, dilution and deposition in
the VC 10 Smoking Robot remains largely undefined and
uncharacterised. Therefore, this study assesses the distri-
bution of tobacco smoke, both particulate and vapour
phase, combined with biological responses in vitro using
the VC 10 Smoking Robot in order to characterise the sys-
tem. To quantify particulate deposition, we used a real-
time quartz crystal microbalance (QCM) tool [20,24,26].
Carbon monoxide (CO) concentrations were measured to
establish vapour phase dilution characteristics and finally,
we used two biological systems, the Neutral Red uptakeVitrocell® VC 10 smoke exposure system. [a] Computer, software
rs and key machine settings. [b] Smoking Robot carousel where
n hood. [c] Piston/syringe which draws and delivers an ISO or Health
smoke dilution system. In our set-up smoke is exhausted to the
transit and delivery of whole smoke occurs in the dilution bar, of
s diluting air is added perpendicular to the mainstream smoke in the
r jets of 2.0 mm diameter. Airflow rates are set by mass flow meters,
system is continuously transiting through to exhaust. [e] Smoke
S) which holds the Transwells® or agar plates which are maintained at
re module via negative pressure applied through a vacuum pump at
oke ‘trumpet’ inlets and, due to the linear configuration, each culture
ion system. The central islands can be removed and quartz crystal
sition 4.
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Both particulate deposition and vapour phase dilution
showed correlations of R2 = 0.975 and R2 = 0.987 respect-
ively with diluting airflow (L/min). Regional smoke depos-
ition across the linear exposure module showed no
statistical difference at any of the airflows tested (0.5-
4.0 L/min), demonstrating uniform deposition within the
chamber at all positions within this system. Furthermore,
real-time deposition data was obtained in situ of exposure
for both the NRU and Ames assays (1.0-12.0 L/min). Fi-
nally, biological data from both assays has been presented
as a function of real-time deposited mass obtained concur-
rently with biological exposure, with associated correla-
tions of R2 = 0.84 and R2 = 0.76 respectively.
Results
Measurement of deposited mass
Four QCMs were installed into a Vitrocell® 6/4 CF Stain-
less Steel module and were used to initially assess particu-
late deposition at diluting airflows of 0.5, 1.0, 2.0 & 4.0 L/
min across all four positions within the exposure module.
The data demonstrates that there is a clear relationship
between increased airflow, smoke dilution and decreased
smoke particulate deposition (R2 = 0.975). At the highest
concentration of smoke tested, which corresponds to a di-
lution airflow of 0.5 L/min, we were able to quantify a
mean particulate deposition of 5.9 ± 0.36 μg/cm2 over a
24 minute exposure. For 1.0, 2.0 and 4.0 L/min airflows,
the mean recorded mass was 3.3 ± 0.28, 1.6 ± 0.23 and 0.6
± 0.08 μg/cm2 respectively (Figure 2).
Initial characterisation of the VC 10 using QCM tech-
nology was conducted as previously described [24] up toFigure 2 Measurement of deposited particulate mass from a 24 minu
0.5-4.0 L/min [a] and reciprocal airflow (1/airflow (L/min)) of; 2.0, 1.0, 0.
Results are based on three independent experiments with four QCM readin
deposited mass values. For airflows of 0.5, 1.0, 2.0 and 4.0 L/min mass value
obtained respectively. [b] shows data presented as a reciprocal of the airflo
95% confidence (red dash) and probability (grey dash) intervals.the 4.0 L/min airflow. However, in this study we have
used QCM technology to assess deposited mass at air-
flows of 1.0-12.0 L/min after a 184 minute exposure
(NRU) and after a 24 minute exposure (Ames), demon-
strating the versatility of this tool. In addition to as-
sessing total deposited mass across the dilution airflow
range, a four QCM approach enabled the assessment of
particulate deposition across the linear exposure module
at all airflows tested (0.5–4.0 L/min). Although a slight
ascending gradient in deposited particulate mass was ob-
served across the module at airflows 0.5 and 1.0 L/min,
no statistical difference was observed between QCM po-
sitions at any of the airflows tested (0.5 L/min p-value
0.347, 1.0 L/min p-value 0.059, 2.0 L/min p-value 0.842,
4.0 L/min p-value 0.296 - Figure 3).
Measurement of deposited mass in situ
To measure deposited mass in situ of exposure, a single
QCM unit remained installed in the final position (position
4) within the Vitrocell® exposure module (mammalian 6/4
CF and Ames). This allowed the direct monitoring of real-
time particulate deposition, which gave a measure of
smoke exposure conditions during in vitro exposure.
Furthermore, this set-up enables biological data to be
presented as an actual function of deposited mass
obtained in real-time during exposure (Table 1).
Carbon monoxide
Carbon monoxide (CO) was used as a marker to assess
the vapour phase of tobacco smoke. Using a direct and in-
direct CO sampling method, we were able to detect CO
concentration differences across the full airflow rangete ISO smoke exposure using 3R4F cigarettes at airflows
5 and 0.25 respectively [b], with a vacuum of 5 ml/min/well.
gs per experiment. [a] shows an individual value plot of obtained
s of 5.9 ± 0.36, 3.3 ± 0.28, 1.6 ± 0.23 and 0.6 ± 0.08 μg/cm2 were
w (1/airflow (L/min)) with a regression fit correlation of R
2 = 0.975 with
Figure 3 A box plot showing deposition across the four QCM positions (1–4, left to right) within the module at airflows tested
(0.5-4.0 L/min). There were no statistical differences between QCM positions 1–4 within the exposure module at any of the airflows tested
(0.5 L/min p-value 0.347, 1.0 L/min p-value 0.059, 2.0 L/min p-value 0.842, 4.0 L/min p-value 0.296). Results are based on three independent experiments.
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clear dose response relationship between CO and air-
flow (L/min), with a regression correlation of R2 = 0.921
and R2 = 0.987 for the direct and Indirect technique re-
spectively (Figure 4).
Neutral Red uptake
The cytotoxicity of 3R4F cigarette smoke was assessed
using the NRU assay across a representative range of
the VC 10s dilution capability (12.0-1.0 L/min). A clear
cytotoxic dose response was observed with increased
smoke concentrations (12.0, 8.0, 4.0 and 1.0 L/min).
The airflow ranges tested produced minimal to com-
plete cell death. Balb/c 3 T3 cells showed no significant
decrease in viability when exposed to a control airflow
(air controls exposed at 0.2 L/min, 5 ml/min/well) to
simulate exposure conditions. In addition to relative
survival, QCM deposition data was obtained during
whole smoke exposure to obtain concurrent particulate
dose values. This enabled relative survival data to beTable 1 Biological and deposited mass values at all airflows t
NRU
(184 minute exposure)










1.0 1.000 22.8 ± 1.7 −2.5 ± 3.
4.0 0.250 3.5 ± 0.1 16.7 ± 7.
8.0 0.125 0.8 ± 0.1 69.9 ± 13
12.0 0.080 0.1 ± 0.1 96.8 ± 10
Deposition data was obtained in situ from a 184 and 24 minute smoke exposure fo
R2 = 0.763) respectively.presented as a function of deposited mass. For example;
airflows of 12.0, 8.0, 4.0 and 1.0 L/min produced viabil-
ities of 96.8 ± 10.1, 69.9 ± 13.0, 16.7 ± 7.4 and −2.5 ±
3.3% with corresponding deposited mass values of 0.1 ±
0.1, 0.8 ± 0.1, 3.5 ± 0.1 and 22.8 ± 1.7 μg/cm2 respecti-
vely. A deposited mass IC50 was calculated at approxi-
mately 1.7 μg/cm2. When data was log transformed a
correlation (R2 = 0.84) between increased cytotoxicity
and deposited mass was observed (Figure 5).
Ames
Ames (YG1042) reverse mutation data correlated with in-
creased smoke concentrations. Airflows 12.0, 8.0, 4.0 and
1.0 L/min following a 24 minutes exposure showed mean
revertant counts of 21.2 ± 5.0, 30.2 ± 4.1, 53.1 ± 9.6 and
78.6 ± 20.6 respectively. In addition to mean revertants and
fold increases (compared to air controls), QCM deposition
data was obtained during whole smoke exposure for con-
current dose measurements. When the biological data
were log transformed a correlation between fold increaseested
AMES
(24 minute exposure)











3 2.30 ± 0.14 5.9 ± 1.6 78.6 ± 20.6
4 0.50 ± 0.10 4.0 ± 0.9 53.1 ± 9.6
.0 0.09 ± 0.02 2.2 ± 0.4 30.2 ± 4.1
.1 0.03 ± 0.01 1.6 ± 0.5 21.2 ± 5.0
r NRU (Correlation R2 = 0.847) and the Ames assay (Correlation
Figure 4 Measurement of carbon monoxide concentrations using a ‘direct’ and ‘indirect’ technique following a 16 minute ISO smoke
run using 3R4F reference cigarettes at airflows 1.0, 4.0, 8.0 and 12.0 L/min [a] and reciprocal airflow (1/airflow (L/min)) of; 1.0, 0.25,
0.125 and 0.080 respectively [b], with a vacuum of 5 ml/min/well. Results are based on three independent experiments per airflow. [a]
Shows an individual value plot of obtained for CO concentrations (μg/ml) and comparisons of concentrations obtained using two independent
techniques, one real time and direct technique and one indirect gas-bag technique. For airflows 1.0, 4.0, 8.0 and 12.0 L/min using the direct
technique CO concentrations were, 0.8 ± 0.2, 0.3 ± 0.01, 0.2 ± 0.01, and 0.1 ± 0.005 μg/ml and using the indirect technique, CO concentrations of
1.4 ± 0.1, 0.4 ± 0.04, 0.1 ± 0.01, and 0.1 ± 0.01 μg/ml were obtained respectively. [b] Shows data presented as a reciprocal of the airflow
(1/airflow (L/min)) with a regression fit correlation of R
2 = 0.921 for the direct and R2 = 0.987 for the indirect technique.
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observed (Figure 6).
Discussion
Assessment of tobacco smoke in vitro has traditionally
focused on the particulate phase captured on a Cam-
bridge filter pad and eluted in DMSO [14] or bubbled
through cell culture media or PBS [27]. However, theseFigure 5 Measurement of percentage relative survival presented as a
exposure [a] and as a Log10 conversion [b] following a 184 minute (2
mass for airflows 1.0, 4.0, 8.0 and 12.0 L/min were 22.8, 3.5, 0.8 and 0.1 μg/
[b] Using a Log10 conversion and regression analysis, the relative survival d
obtained in situ (R2 = 0.84) with confidence intervals (red dash) and probab
independent experiments.techniques do not capture the full extent of the vapour
phase of cigarette smoke and semi-volatiles which not
only make up the majority fraction of tobacco smoke,
but include reactive chemicals with known toxicological
properties [7]. Whole smoke exposure technologies exist
and are gaining traction as they become more widely
used, characterised and developed alongside biological
end-points [21-23,28]. To ensure the full interactions offunction of deposited mass which was captured in situ of
3 cigarettes) 3R4F smoke exposure period. [a] Average deposited
cm2 respectively. The calculated deposited mass IC50 was1.7 μg/cm2.
ata showed a positive correlation with increased deposited mass
ility intervals (grey dash) of 95%. Results are based on three
Figure 6 Measurement of Ames mutation fold increases presented as a function of deposited mass which was captured in situ of
exposure [a] and as a Log10 conversion [b] following a 24 minute (3 cigarettes) 3R4F smoke exposure period. [a] Average deposited
mass values for a 24 minute exposure for airflows 1.0, 4.0, 8.0 and 12.0 L/min were 2.30 ± 0.14, 0.50 ± 0.10, 0.09 ± 0.02 and 0.03 ± 0.01 μg/cm2
respectively. [b] Using a Log10 conversion and regression analysis fold mutation frequencies showed a positive correlation with deposited mass
obtained concurrently with biological data (R2 = 0.763) with confidence intervals (red dash) and probability intervals (grey dash) of 95%. Results
are based on three independent experiments.
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VC 10 Smoking Robot and determined particulate de-
position using QCM technology as a stand-alone charac-
terisation tool to look at regional deposition, and also in
situ of exposure. In addition, we have used carbon mon-
oxide as a vapour phase marker of whole smoke and fi-
nally, produced repeatable biological dose-responses
using two independent in vitro systems.
To measure deposited mass prior to biological expos-
ure we used four QCMs installed into a 6/4 CF Stainless
Steel Vitrocell® module and demonstrated that depos-
ition was closely correlated with airflow (R2 = 0.975) with
a deposited mass range of 5.9–0.36 μg/cm2 at a diluting
airflow range of 0.5-4.0 L/min. A slight ascending con-
centration gradient across the exposure module was ob-
served at airflows 0.5 and 1.0 L/min. However, in this
study no statistical difference was observed between
QCM positions at any of the airflows tested (0.5 L/min
p-value 0.347, 1.0 L/min p-value 0.059, 2.0 L/min p-
value 0.842, 4.0 L/min p-value 0.296). In addition to
QCMs allowing dose to be measured in real-time in situ
of exposure, we propose that this technology can be
used as a machine QC tool, to assess dilution and depo-
sition performance over longer periods of time. Initial
deposited mass characterisation was conducted in ac-
cordance to a previously published study by Adamson
et al., 2013 [24]. The results from this study show simi-
larities between systems for total deposited mass. How-
ever, Adamson et al., 2013 [24] observed differences in
the positions of the linear exposure module, whereas this
study did not. This highlights the importance of under-
standing dilution and deposition data in each independentVC 10 system. We further utilised QCM measurements
by exposing QCMs in conjunction with biological assays
at all dilutions tested (1.0-12.0 L/min), demonstrating the
versatility of this tool.
As whole smoke is made up of two distinct phases, it
is important to characterise these phases individually.
Therefore, we used CO as a vapour phase marker and
characterised dilution concentrations within this set-up.
Measuring CO concentrations in an in vitro exposure
system has associated logistical challenges. For example,
the CO analyser has an independent pump that pulls the
diluted smoke aerosol through. Connecting this in-line
can cause pressure differential problems within the system
or can create a flow artefact which may affect results at
low airflows. Alternatively, smoke can be captured in a
Douglas bag and analysed post-exposure. This technique
has the limitation that analysed smoke is artificially aged
prior to analysis. In this study, we analysed CO concen-
trations within the system using both techniques. An
in-line real-time ‘direct’ technique and an off-line post ex-
posure ‘indirect’ technique. Both measurement techniques
produced strong R2 correlations. However, the direct tech-
nique produced a lower correlation (R2 = of 0.921) com-
pared to the indirect one (R2 = 0.987) and also showed a
higher variation in terms of measured CO concentration
again compared to the indirect technique. From a QC
point of view, measuring CO using a gas bag technique is
appropriate as this can be conducted outside the usual ex-
perimental conditions, or to assess changes in the system
set-up. However, an in-line technique provides valuable
real-time information on the exposure conditions and
cigarette performance. Higher variations in the direct
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CO concentrations as defined by puffing profiles, and are
not present in the indirect technique as it is an homo-
genous mixture captured over the duration of the exposure
period. Unfortunately, an indirect technique cannot be used
for long exposure periods, due to the nature of gas capture
in a Douglas bag. We propose the use of both techniques
in combination to fully characterise the exposure system
and to support in vitro exposure scenarios.
We also assessed the reproducibility of biological re-
sponses from two independent biological systems, using
the Ames and NRU assays. Tobacco smoke produced a
complete cytotoxic dose–response across the range of
airflows tested (1.0-12.0 L/min) which corresponded
with increased particulate deposition. The results dem-
onstrated a deposition IC50 of 1.7 μg/cm
2 for a 3 hour
exposure. Moreover, the Balb/c cells were unaffected by
a control airflow and were able to withstand the 3 hour
exposure period with good viability, demonstrating their
suitability for long term in vitro tobacco smoke exposure
at the ALI. The Ames reverse mutation assay with strain
YG1042 also demonstrated consistent biological re-
sponses, similar to that reported in a previous whole
smoke study [29]. In this assay, mean revertants and fold
increase in colony numbers were observed in a dose
dependent manner with increasing concentrations of to-
bacco smoke and particulate deposition. The response
from three independent experiments for both biological
systems were consistent, indicating a stable exposure
set-up. However, assessment of biological robustness
and/or repeatability for both assays has yet to be fully
assessed using the VC 10.
In this study we have presented biological data as a
function of deposited mass and have defined deposited
mass as the total accumulative weight deposited on the
QCM crystal over the exposure period. Currently, we be-
lieve this reflects the particulate fraction of smoke with
the possibility of some associated volatile or vapour phase
compounds. However, the exact make up and distribution
of the deposited mass fraction in this set-up has yet to be
qualified or quantified and remains an area of interest. We
believe that both smoke fractions are important and have
distinct contributions to biological effect and It is there-
fore important to characterise both phases of cigarette
smoke within these exposure systems.
Finally, deposited mass measurements obtained from
the 6/4 CF module were different to those obtained from
the Vitrocell® - Ames module at a 1.0 L/min over a 24 mi-
nute exposure. The 6/4 CF module gave a deposited mass
reading of 3.3 ± 0.28 μg/cm2, whereas the Ames module
gave 2.30 ± 0.14 μg/cm2. Although both supplied by
Vitrocell® and designed to be used interchangeably with
the VC 10 Smoking Robot, both chambers have slight vari-
ations in the width of the trumpet inside the module. TheAmes module has agar-plate inserts that measure a diam-
eter of 35 mm, whereas the 6/4CF module uses 24 mm
Transwells®. To accommodate this, the trumpet circum-
ference is larger in the Ames module compared with that
of the 6/4 CF module. We propose the difference in trum-
pet circumference may have an impact on smoke veloci-
ties and therefore diffusion and deposition within the
chamber. However, this difference was only observed at
the 1.0 L/min airflow, and therefore may only be related
to higher smoke concentrations that the 1.0 L/min dilu-
tion (or lower) would deliver. A more detailed study would
need to be conducted to examine this observation further.
Materials and methods
Chemicals and reagents
All chemicals and reagents were obtained from Sigma-
Aldrich (Gillingham, UK) unless otherwise stated. All
tissue culture media was obtained from Gibco® via Life
Technologies (Paisley, UK).
Smoke generation
Cigarette smoke was generated using a Vitrocell® VC 10
Smoking Robot, Serial Number - VC10/090610 (Vitrocell®
Systems, Waldkirch, Germany). Smoke dilutions were
achieved by diluting in air (L/min), with a vacuum of
5 ml/min/well for all experiments. Flow and vacuum rates
within this system were set using mass flow meters
(Analyt-MTC GmbH, Mülheim, Germany) prior to exper-
iments. For all experiments, the VC 10 smoked to the ISO
smoking regime (35 ml puff over 2 seconds, once a mi-
nute). Kentucky 3R4F (9.4 mg) reference cigarettes (Uni-
versity of Kentucky, Kentucky, USA) were used exclusively
in this study.
Cell culture
Mouse fibroblasts (Balb/c 3 T3 clone A31) were used in
the NRU assay and were obtained from the European
Collection of Cell Cultures. Balb/c 3 T3 cells were
maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM) containing 4 mM glutamine and 4.5 g/L glu-
cose supplemented with 10% foetal calf serum and peni-
cillin/streptomycin, at 37 ± 1°C in an atmosphere of 5%
CO2 in air.
Bacteria
Salmonella typhimurium (strain YG1042) was used in the
Ames assay and obtained from the National Institute of
Health Science (Tokyo, Japan). The bacterial strain
YG1042 is a derivative of strain TA100 with a histidine
base-pair substitution [30]. It carries an additional plasmid
(pYG233) encoding for overexpression of nitroreductase
and O-acetyltransferase genes. Bacteria were cultured at
37 ± 1°C for 8 hours in nutrient broth, containing Ampi-
cillin (25 ug/ml) and Kanamycin (25 ug/ml) to obtain cells
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ments were carried out according to previous reported
methodologies [30-32].
Carbon monoxide
Carbon monoxide (CO) concentrations were determined
via the analysis of the diluted mainstream cigarette
smoke using a Signal® 7000-FM gas analyser (Surrey,
UK). Two techniques were explored, a ‘direct’ technique,
where the gas analyser was attached directly to the dilu-
tion system and CO concentrations were measured in a
real-time format during exposure. The ‘indirect’ tech-
nique was utilised to capture cigarette smoke in a
Douglas bag (Borgwaldt, Germany) and CO concen-
trations were analysed post-exposure. Due to the high
volume of diluting air, a 10 or 120 L Douglas bag was
used as appropriate. For both techniques, two 3R4F ciga-
rettes were smoked under ISO conditions (8 puffs per
cigarette) using airflows, 1.0, 4.0, 8.0 and 12.0 L/min.
Measurement of particulate mass
For measurement of particulate deposition within the
exposure module, four QCMs (Vitrocell® Systems
GmbH, Waldkirch, Germany) were installed into a 6/4
CF Stainless Steel Vitrocell® exposure module as previ-
ously described [24]. QCM technology has been incor-
porated into a variety of exposure chambers [20,24,26]
and has been shown to correlate strongly with parti-
culate spectrofluorescence techniques [20]. Prior to
smoke exposure, the QCM module was acclimatised
for several minutes prior to the baseline being set to
zero. During the whole smoke generation and exposure
phase, the QCM took mass readings every 2 seconds in
real-time. Final deposited mass readings were only
taken once the cigarette smoke had finished depositing
onto the crystal, observed through a plateau phase in
the real-time trace. Individual QCM positions across
the linear module (1–4, distal and proximal to exhaust)
were compared to assess regional deposition values
across the module. In addition, data has also been
presented as a function of deposited mass and as a re-
ciprocal of airflow (1/airflow (L/min)).
During biological exposure, three QCMs were re-
moved from the module leaving one QCM installed in
the fourth position. This allowed exposure of replicate
Transwells® (NRU) or Agar plates (Ames) for biological
analysis and one QCM for in situ measurement of par-
ticulate dose. Biological data are presented as a function
of deposited mass (μg/cm2) obtained in situ of exposure.
Neutral Red uptake
Balb/c 3 T3 cells were seeded into 24 mm Transwells®
(Corning Incorporated via Fisher Scientific, UK) in 6-
well plates and maintained in culture for approximately24 hours to form a near-confluent monolayer. Cells were
then exposed at the ALI to freshly generated cigarette
smoke from the Vitrocell® VC 10 Smoking Robot. After
exposure (184 minutes, 23 Cigarettes, 8 puffs per
cigarette at airflows of 1.0, 4.0, 8.0 and 12 L/min) cells
were incubated in DMEM containing 50 μg/mL Neutral
Red (Sigma-Aldrich, UK) for 3 hours. Excess Neutral
Red was washed away. The dye which was stored intra-
cellularly was released by the addition of de-stain solu-
tion (ethanol: acetic acid: distilled water; (50:1:49)) and
measured by absorbance at 540 nm. NRU was deter-
mined for each treatment dilution and compared to that
of control cultures (air controls exposed at 0.2 L/min).
Relative survival was calculated by subtracting a blank
Neutral Red treated Transwell® and normalising to the
air control.
Ames
Salmonella typhimurium strain YG1042 was used in the
presence of a 10% exogenous mammalian metabolic ac-
tivation system (Aroclor 1254-induced rat liver S-9,
(MolTox®, Molecular Toxicology, Inc, USA )). In brief,
approximately 2x107 bacterial cells were plated on to
35 mm Vogel-Bonner E agar plates in 10% S-9 buffer
(prepared according to Maron and Ames [31] with
48.8 μg/mL biotin and 40 μg/mL histidine) using a
spread plate methodology. Plates were then transferred
to an anhydric incubator set at 37°C until dry. For
smoke exposure, agar plates were transferred to the
Vitrocell®-AMES module and exposed for 24 minutes (3
cigarettes, 8 puffs per cigarette) at airflows 1.0, 4.0, 8.0
and 12.0 L/min. Following exposure, plates were incu-
bated for a further 3 days. Each plate was examined for
signs of toxicity before scoring for revertant colonies
(Sorcerer Image Analyser, Perceptive Instruments, Ha-
verhill, UK).
Statistics
All experiments were conducted on three independent oc-
casions at airflows between 0.5-12.0 L/min with a set
5 ml/min/well vacuum. All graphs were created using
MINITAB® version 16.1.0 statistical software. Statistical
analysis of QCM position and deposited mass within the
chamber was determined by one-way analysis of variance
(ANOVA) in Minitab® 16.1.0 using Tukey’s method with a
confidence level of 95.0%. Table 1 was constructed using
Microsoft Excel® and show mean data ± standard deviation
values for all experiments.
Conclusions
Here we describe a study that significantly increases our
working knowledge of the Vitrocell® VC 10 Smoking
Robot. We conclude that in our study, under the experi-
mental conditions tested, the VC 10 can produce stable
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http://journal.chemistrycentral.com/content/7/1/146tobacco smoke dilutions, as demonstrated by particulate
deposition, measured vapour phase smoke marker de-
livery and biological responses from two independent
in vitro systems. In this study biological data has been
presented as a function of deposited mass obtained in
real-time in situ of exposure, giving our biological data
a gravimetric measure. We believe that this data can
be better compared to others using a similar gravimetric
approach irrespective of exposure system and set-up. We
have not as yet addressed whether these responses can be
reproduced by other VC 10 users and how variable VC
10s are from machine-to-machine and location-to-lo-
cation. However, we now have the tools, techniques
and applied knowledge to start addressing some of
these questions.
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